Contents

How to survive and thrive during the biotech crunch 4
Record memberships & attendance at Swiss Biotech Day 5
Swiss Biotech Ventures platform 6
Highlights of the Swiss Biotech Association in 2022 8
Swiss Biotech Success Stories 10
  Award winners 2019 – 2022 12
  Open up your network 15
In the media 16
Digital platforms and publications 17
Financial statements 2022 18
Development in numbers 21
Partner network 22
Our members 24
About the Swiss Biotech Association 28
 Preferential business solutions for our members 30
Supporting the Swiss biotech hub: Objectives for 2023 33
How to survive and thrive during the biotech crunch

2022 was a difficult year for the biotech industry. The global economic situation and the correction in the US biotech environment led to tremendous pressure on all companies. First, it hit most listed enterprises, struggling to get adequate financing while often trading below the cash on their balance sheets, and then the correction expanded to the private sector. Funding is scarce and will continue to drive the agenda in 2023.

My presidency of the Swiss Biotech Association started in a challenging moment for our industry. Investors are holding back with funding, and, despite the low price tags, large pharmaceutical companies are not taking over biotech companies.

At the same time, I am very confident that the future of our industry is bright, and will be unlocked if we focus on our purpose, our core strengths and deliver results with impact.

I started Molecular Partners almost 20 years ago with the sole purpose to help patients that have no, or no satisfying options to treat their diseases. I believe in innovation and that dedicated teams with a common purpose can make a difference for patients. The same belief motivated me to take the lead of the Swiss Biotech Association’s board. We have great companies in our country, covering all aspects of biotech, and it is not by chance that we have been at the top of worldwide innovation indexes for many years.

Other Swiss virtues drive my confidence that we will come out of this challenging period stronger than ever – we are resourceful, agile and cost-effective. I urge all of us to continue the great work, remain pro-active and positive, keep a relentless focus on our purpose to deliver value for patients and drive innovation. With the right spirit, we will turn the current sentiment in the biotech industry. It is my and the association’s pleasure and duty to support all of you to drive the change ahead of us.

The future remains bright and we can look back with pride as we are celebrating the 25th anniversary of our association this year. I’m looking forward to reflecting on and celebrating all the great success stories we were able to share over the years. The timing is ideal to come together, learn from the past, get energized and shape the future of our industry. It is my pleasure welcoming you to the Swiss Biotech Day or at any other of our events in 2023.

Sincerely yours,

Patrick Amstutz
President Swiss Biotech Association
Record memberships & attendance at Swiss Biotech Day

With 1,200 participants from 36 countries, the 2022 edition of the Swiss Biotech Day was the biggest and most international so far. Some 37% of the participants joined from abroad and for the first time, our flagship event was held over one and a half days and offered the Global Village partnering platform for international delegations.

After two years of record funding – in 2020 and 2021 Swiss biotech companies attracted more than CHF 6.5 billion – 2022 proved to be a more challenging funding environment. Overall, we were back to pre-Covid levels. The publicly listed companies suffered from the poor global market sentiment for biotech companies. However, CDR-Life and ImmunOs Therapeutics demonstrated that the private-financing market in Switzerland held up better than the public, with each closing financing rounds in excess of CHF 70 million.

From the perspective of the Swiss Biotech Association, 2022 was a very successful year:

- 86 new members joined our member base and at the end of 2022 we listed a record number of 443 members in the Swiss Biotech Directory
- More than 100 co-promotion partners promoted the Swiss Biotech Day within their member and biotech communities
- The Swiss Biotech Day was successfully extended into a 1.5 day format and attracted close to 1,200 participants from 36 countries (37% joined from abroad)
- The Swiss Biotech Ventures platform was established as a valuable online marketplace for Swiss biotech companies, global investors and industry partners, facilitating financing and partnering

In 2022 we used this support to:

- Accelerate onboarding to the Swiss Biotech Ventures platform to match biotech ventures, investors, and pharma partners
- Expand the Swiss Biotech Association team: Aditya Yellepeddi joined as the Liaison Romandie, Carsten Laue supports funding and the community platforms, Annamaria Kauzlaric looks after member support and Franz Waibel heads up the Global Village platform
- Secure an effective networking presence through the Swiss Pavilions at BIO US and BIO Europe, and through free access to the BiotechGate partnering for our members
- Provide strong advocacy through our collaborations with Interpharma, scienceindustries, economiesuisse and the international council of biotech associations
- Promote the value and contribution of the Swiss biotech industry. The great contributions of Genedata and Etienne Jornod were honored with the Swiss Biotech Success Stories Award

Our objectives for 2023 are outlined on pages 33–34. Please reach out to our board members and the management team (see p. 28) with your feedback, and support us in providing a strong voice for the Swiss biotech ecosystem.

Yours faithfully,

Michael Altorfer
CEO
Swiss Biotech Ventures platform

Swiss biotech companies, global biotech investors and industry partners equally benefit from the Swiss Biotech Ventures platform. It is free of charge and matches Swiss biotech companies, global biotech investors, and industry partners to facilitate financing, licensing and research collaborations.

With the Swiss Biotech Ventures platform, the Swiss Biotech Association enables Swiss biotech companies to present their investment and partnership opportunities to global biotech investors and multinational pharma and industry partners. Investors, family offices, foundations and pharmaceutical companies gain insight into the pipeline of the Swiss biotech hub, and easily discover and contact companies matching their strategic focus based on modalities, indications, and development stage.

Only 18 months after launch, Swiss Biotech Ventures has developed into a comprehensive database that creates transparency between stakeholders. On the “sell side”, Swiss biotech companies describe their ventures. On the “buy side”, global biotech investors and pharmaceutical representatives identify investment and partnership opportunities. Both sides present their focus and goals, rendering matchmaking between these players more efficient and transparent.

Swiss Biotech Ventures is steadily growing. At the end of 2022, more than 750 investor and pharmaceutical companies were listed, and Swiss biotech companies presented more than 150 innovative venture projects. Every time a venture is added or its status changes (e.g. from preclinical to clinical phase I), interested parties receive an email notification and can find out more on the platform.

Both sides gain valuable time as individual communication on the project development is replaced by timely, transparent and consistent information. In the Swiss tradition, the Swiss Biotech Association takes a neutral stance. No company is promoted, no privileged information is shared with any of the parties, nor does the Swiss Biotech Association receive any deal commissions. Anyone on the platform has free access to identical information, simultaneously, transparently and to the benefit of all parties.

In conjunction with the Swiss Biotech Ventures platform, the Swiss Biotech Association also helps companies to present and partner at the Swiss Biotech Day and at national and international events. Quarterly highlight reports from the Swiss biotech industry with background information complete the offering.

Join Swiss Biotech Ventures and gain access to:

- free of charge platform, by invitation only
- matching Swiss biotech companies with global biotech investors and industry partners to facilitate financing, licensing and research collaboration
- timely, transparent, simultaneous and consistent information
- a steadily growing database of thriving biotech ventures
- free newsletters on Swiss biotech venture highlights and background information

Register on ventures.swissbiotech.org now and promote Swiss Biotech Ventures amongst your peers around the globe.
I am an investor or industry partner

Get an exclusive access to Swiss Biotech Ventures.
Identify ventures in your areas of interest, and contact or follow up your favourite projects.

Create an account (free)  More information

I am the leader of a Swiss biotech venture

Make your academic project or spin-off visible to trusted investors and industry partners.
Increase your chances of successful funding or partnership, now or in the future.

Create an account (free)  More information
Highlights of the Swiss Biotech Association in 2022

A new president for the Swiss Biotech Association: Molecular Partners’ Chief Executive Officer Patrick Amstutz was elected, and succeeds Dominik Escher.

The Swiss Biotech Day – our largest and most international event ever with close to 1,200 participants from 36 countries, the launch of the Global Village for international biotech delegations, and a welcome note by the President of the Swiss Confederation, Ignazio Cassis.

The Swiss Biotech Report 2022, our flagship publication, outlined very strong capital investments in Swiss biotechs of CHF 3.3 billion and R&D investments aggregating to a new record of CHF 2.6 billion.

Switzerland’s leading Swiss Biotech Directory with more than 1,000 company entries celebrated its 10th anniversary.

Participated at roundtables at the WEF to discuss collaboration possibilities with India, at the national antibiotics research program “Round Table Antibiotics”, and collaborated with Swissmedic and the Federal Office of Public Health on pandemic preparedness.

Launch of Swiss Biotech Orbit, the job and talent matching platform for biotech talents, which is extended in 2023 after its pilot phase for refugees from the Ukraine.
The annual Swiss Biotech CEO meeting, and biotech CEO networking events with investors and multi-national pharma companies build up a peer community.

Representing the Swiss biotech industry in economiesuisse’s health policy and education and research commissions, as well as in the joint intellectual property commission of Interpharma and scienceindustries. Engaging in a supportive dialogue with Swissmedic and the Federal Office of Public Health and collaborating with the Swiss Agency for Development and Cooperation (DEZA) on voluntary licensing.

Supported the new SME stock exchange Sparks by SIX and the first listing of Xlife Sciences to enable Swiss biotechs to access the public capital markets.

Presented Swiss biotechs and the association in the Swiss pavilion at BIO International and the BIO Europe convention, at the Sachs Associates’ investor conferences, the LSX World Congress, Illmac, the Swiss HLG conference, and more.

New colleagues joined the team (see p. 28) to strengthen the member engagement and increase our impact in all Swiss regions and internationally.

Go from Funding Series A, B, C... To SIX.

Fire up your growth ambitions with a Sparks listing.

The Swiss Biotech Association team is growing and we sincerely thank Heike Bihlmann for her many years of representing the Swiss Biotech Association in the Basel region and supporting our members. In 2022, four new colleagues joined the team (see p. 28) to strengthen the member engagement and increase our impact in all Swiss regions and internationally.
Swiss Biotech Success Stories demonstrate the power and potential of the industry

The Swiss Biotech Success Stories Awards recognize valuable accomplishments and honor those who have made important and sustainable contributions to the biotech industry in Switzerland. The awards are presented each year at the Swiss Biotech Day and reflect the diversity and achievements of this innovative sector.

Switzerland is one of the world’s leading biotech hubs and attracts many foreign companies, specialists and investors. It provides over 50,000 jobs and, together the biotech and pharmaceutical industries, account for more than 40% of Swiss exports.

To make the industry’s impact more visible, the Swiss Biotech Success Stories initiative was launched in 2018. Selected success stories are showcased to illustrate how Swiss biotech companies help patients, improve health care worldwide, and make a valuable and significant contribution to the Swiss and global economy.

Laureates are individuals or groups who have earned extraordinary merits. Success is broadly defined as scientific, translational, medical or commercial, together with other aspects that have a positive impact on the biotech and life science industry and society in Switzerland.

“It is essential to share with the public the importance and success factors of biotech companies and ensure that decision-makers understand what it takes for the industry to develop and remain competitive,” says Michael Altorfer, CEO of the Swiss Biotech Association. “Young talent should be inspired and motivated to take a closer look at the great variety of career profiles in biotech.”

12 success categories

- Completed achievement with lasting impact
- Scientific breakthrough
- New technology
- Strong impact on society
- Product approval and sustainable revenues
- Important IP, innovative deal-making, acquisition
- Involvement of one or more Swiss citizens
- Swiss-based company / institution
- Creation of jobs in Switzerland
- Other aspect with a direct link to Switzerland
- Enabler for the biotech industry
- Swissness: Think global, made in Switzerland
A big thank you to our partners

**Sponsors**

The Swiss Biotech Success Stories Awards are also supported by

**WISSENSCHAFT. BEWEGEN | Basel-Stadt | TS Kommunikation**
Headquartered in Allschwil, Actelion is part of the Johnson & Johnson Family of Companies. Its ground-breaking research and medicines have been a key contributor to improve the lives of people affected by pulmonary hypertension, and made Actelion an industry leader in this area.

Bachem is a leading manufacturer of peptides and oligonucleotides. The company has grown over 50% in the last five years and now offers more than 5,500 different biologically active peptides amino acid derivatives and oligonucleotides. Its investment plans call for the investment of over USD 400M to continue to pursue its growth strategy.

Basilea Pharmaceutica is a leader in targeted oncology small molecules, novel antibiotics and antifungals. Since its listing in 2004 (SIX: BSLN), Basilea has launched two anti-infective treatments: Cresemba (isavuconazole) for invasive fungal infections and Zevtera (ceftobiprole), an antibiotic for severe hospital bacterial infections.

Headquartered in Zug, Biogen has been a key stimulus and model for the biotech industry. Its best-selling drug for multiple sclerosis or its Alzheimer’s candidate, as well as the new production facilities in Luterbach, creating 600 new jobs, are proof of Biogen’s success.

Family-owned Debiopharm from Lausanne, identifies high-potential compounds in oncology and for the treatment of bacterial infections. They are tested in clinical development and licensed to business partners globally. Over a million patients benefit from their therapies every year.

ESBATech, now a Novartis company, is recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications. The most advanced product from the ESBATech platform received market approval by the FDA in October 2019 and shortly thereafter in all major markets.
Etienne Jornod

Etienne Jornod, Swiss entrepreneur, was Executive Chairman of the Vifor-Galenica Group delivering 25 consecutive double-digit net profit growth, supporting millions of patients and creating thousands of jobs. In 2020, he acquired OM Pharma with friends, aiming to create a unique biopharmaceutical company based on bacteria lysates expertise.

Genedata

Genedata, global market leader for software solutions that digitalize data-rich and complex bio-pharmaceutical R&D processes, enables an R&D revolution driven by precision medicines and artificial intelligence approaches. It helps the industry to deliver innovative biotherapeutics, vaccines and cell & gene therapies faster.

Glycart

The Schlieren-based company is an integral part of Roche Pharmaceutical Research and Early Development since 2005, and a pioneer in antibody engineering in cancer immunotherapy. Its antibody glycosylation technology increases immune-mediated cancer cell killing and builds the basis for improved cancer medicines.

Helsinn

Helsinn, an important employer in Ticino, has a broad portfolio of marketed cancer care products and a deep development pipeline. It has built significant R&D and manufacturing capacities, also advances patient care and supports healthcare innovation with its investment fund.

Lonza

Lonza is a global leader in contract development and manufacturing services with strong R&D capabilities and world-class facilities across five continents. In 2020, Lonza supported more than 820 preclinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced 230 billion capsules.

Novimmune

Founded by the renowned immunologist, Professor Bernard Mach MD PhD, privately-owned Novimmune is a leading light in the discovery and development of fully-human, antibody-based drugs used to fight autoimmune and inflammatory diseases and cancer.
Fully integrated into GlaxoSmithKline since 2013, Okairos from Basel developed innovative T-cell based vaccines for major infectious diseases such as malaria, hepatitis C, HIV, and Ebola. Its novel replication-incompetent adenovirus vectors could enable the development of important new vaccines and offer immunizations against illnesses that lack vaccines.

The advanced technologies in protein expression by Selexis provide biotech and pharmaceutical companies a rapid, stable, and cost-effective solution for the production of recombinant proteins. Nearly a hundred drug candidates in clinical development and three commercial products utilize the technologies of the Plan-les-Ouates-based company.

The trio of foundations has been supporting biotech startups with great success for more than 10 years, thereby making a significant contribution to the growth of the Swiss biotech industry. They share the nomination for the Swiss Biotech Success Stories Award.

This transformational joint venture provides Vifor Pharma direct access to dialysis patients, facilitating the product distribution and recruitment for clinical development. It transformed the company from Glattbrugg rapidly into a global nephrology corporation. Such vertical integration is a role model for the convergence of different life science sectors.

Werner Arber, Swiss microbiologist and geneticist, won the 1978 Nobel Prize in Physiology or Medicine for his discovery of restriction endonucleases. His groundbreaking research in the field of molecular genetics was instrumental in the development of biotechnology.
Open up your network

To ensure that the Swiss Biotech Success Stories will be visible around the globe in many locations, media and events, help us with your network and distribution power.

Let us know if you have contacts in your network who could benefit from the insight into Swiss Biotech Success Stories, and are curious to learn more about the stunning accomplishments of entrepreneurs in this competitive industry.

Interested parties could be: Your customers, suppliers, partners, a journalist, an investor, your company’s communication unit, your follower base on social media, your favorite politician, an event platform dedicated to life science, your rotary club colleagues or any other possibility, that could help to promote these success stories.

Share with us your suggestions for spreading the word by email to success@swissbiotech.org

...or use the QR code to get to our online form.
In the media

Key articles and interviews mainly in leading Swiss media supported our goal in making sure that the biotech industry got heard in the public. The coverage on Swiss biotech is steadily growing.
Digital platforms and publications

One of the Swiss Biotech Association’s goals is to emphasize the valuable contribution of the biotechnology industry in Switzerland and abroad, and position it as an important value-adding economic pillar. Besides the Swiss Biotech Success Stories (see pages 10–15), our digital platforms and publications support the association’s drive to expand its impact and strengthen its role as the central resource for the Swiss biotech industry.
## Income statement

<table>
<thead>
<tr>
<th>In CHF</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership fees</td>
<td>853,500</td>
<td>729,500</td>
</tr>
<tr>
<td>International projects</td>
<td>3,588</td>
<td>0</td>
</tr>
<tr>
<td>National projects</td>
<td>843,643</td>
<td>481,231</td>
</tr>
<tr>
<td>Website &amp; community platform</td>
<td>7,940</td>
<td>0</td>
</tr>
<tr>
<td>Swiss Biotech Success Stories</td>
<td>5,000</td>
<td>0</td>
</tr>
<tr>
<td>Swiss Biotech Report</td>
<td>48,000</td>
<td>52,000</td>
</tr>
<tr>
<td>Swiss Biotech Directory</td>
<td>27,670</td>
<td>22,910</td>
</tr>
<tr>
<td>Increase/decrease bad debt provision</td>
<td>-8,500</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total income</strong></td>
<td><strong>1,780,841</strong></td>
<td><strong>1,285,641</strong></td>
</tr>
<tr>
<td>Fees to other associations</td>
<td>25,751</td>
<td>26,365</td>
</tr>
<tr>
<td>International projects</td>
<td>49,485</td>
<td>17,037</td>
</tr>
<tr>
<td>National projects</td>
<td>877,596</td>
<td>509,735</td>
</tr>
<tr>
<td>Swiss Biotech Success Stories</td>
<td>14,285</td>
<td>13,717</td>
</tr>
<tr>
<td>Increase/decrease tied capital &quot;Swiss Biotech Success Stories&quot;</td>
<td>-5,000</td>
<td>-5,000</td>
</tr>
<tr>
<td>Swiss Biotech Sounding Board</td>
<td>0</td>
<td>5,253</td>
</tr>
<tr>
<td>Increase/decrease tied capital &quot;Swiss Biotech Sounding Board&quot;</td>
<td>0</td>
<td>-5,000</td>
</tr>
<tr>
<td>Swiss Biotech Report</td>
<td>65,247</td>
<td>60,946</td>
</tr>
<tr>
<td>Swiss Biotech Directory</td>
<td>39,145</td>
<td>31,398</td>
</tr>
<tr>
<td>Website &amp; community platform</td>
<td>45,112</td>
<td>99,553</td>
</tr>
<tr>
<td><strong>Association activities expense</strong></td>
<td><strong>1,111,621</strong></td>
<td><strong>754,004</strong></td>
</tr>
<tr>
<td>Management fees¹</td>
<td>375,454</td>
<td>317,912</td>
</tr>
<tr>
<td>Accounting &amp; member support</td>
<td>168,326</td>
<td>122,468</td>
</tr>
<tr>
<td>Office rent &amp; administration</td>
<td>23,220</td>
<td>26,232</td>
</tr>
<tr>
<td>Consulting</td>
<td>5,991</td>
<td>13,150</td>
</tr>
<tr>
<td>Public relations</td>
<td>69,144</td>
<td>48,399</td>
</tr>
<tr>
<td><strong>Other operating expenses</strong></td>
<td><strong>642,135</strong></td>
<td><strong>528,160</strong></td>
</tr>
<tr>
<td><strong>Financial income result</strong></td>
<td><strong>-8,429</strong></td>
<td><strong>-3,914</strong></td>
</tr>
<tr>
<td><strong>Income from previous reporting periods</strong></td>
<td><strong>0</strong></td>
<td><strong>16,501</strong></td>
</tr>
<tr>
<td><strong>Tax expenses</strong></td>
<td><strong>167</strong></td>
<td><strong>378</strong></td>
</tr>
<tr>
<td><strong>Net profit for the year</strong></td>
<td><strong>18,489</strong></td>
<td><strong>15,686</strong></td>
</tr>
</tbody>
</table>

¹ Management fees related to events and promotional products are directly booked to the respective project.
## Balance sheet

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td><strong>Liabilities</strong></td>
<td><strong>Assets</strong></td>
<td><strong>Liabilities</strong></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>312,436</td>
<td>233,314</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>61,512</td>
<td>22,019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accrued income &amp; prepaid expenses</td>
<td>42,758</td>
<td>16,590</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>416,706</strong></td>
<td><strong>271,923</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td><strong>Assets</strong></td>
<td><strong>Liabilities</strong></td>
<td><strong>Assets</strong></td>
<td><strong>Liabilities</strong></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>147,818</td>
<td>36,064</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accrued expenses &amp; deferred income</td>
<td>84,900</td>
<td>65,360</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Association equity</td>
<td>131,239</td>
<td>131,239</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tied capital for SBA Success Stories</td>
<td>5,000</td>
<td>10,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tied capital for SBA Sounding Board</td>
<td>10,000</td>
<td>10,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retained earnings</td>
<td>19,261</td>
<td>3,575</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net result of the year</td>
<td>18,489</td>
<td>15,686</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>416,706</strong></td>
<td><strong>271,923</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Auditor’s report

Report of the statutory auditor on the limited statutory examination to the general meeting of

Swiss Biotech Association (SBA), Zurich

As statutory auditor, we have examined the financial statements (balance sheet, income statement and notes) of Swiss Biotech Association (SBA) for the financial year ended 31 December 2022.

These financial statements are the responsibility of the association board. Our responsibility is to perform a limited statutory examination on these financial statements. We confirm that we meet the licensing and independence requirements as stipulated by Swiss law.

We conducted our examination in accordance with the Swiss Standard on the Limited Statutory Examination. This standard requires that we plan and perform a limited statutory examination to identify material misstatements in the financial statements. A limited statutory examination consists primarily of inquiries of company personnel and analytical procedures as well as detailed tests of company documents as considered necessary in the circumstances. However, the testing of operational processes and the internal control system, as well as inquiries and further testing procedures to detect fraud or other legal violations, are not within the scope of this examination.

Based on our limited statutory examination, nothing has come to our attention that causes us to believe that the financial statements do not comply with Swiss law and the articles of association.

Zurich, 3 February 2023

BDO Ltd

Manuel Lüthi  ppa. Niklaus Stamm
Licensed Audit Expert Auditor in Charge

Enclosure
Financial statements

BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.
Development in numbers

At the end of 2022, the Swiss Biotech Association counted 443 members. Our website, newsletters and mailings provide an up-to-date and comprehensive picture of what is happening in the Swiss biotech industry. As in the past years, the number of members, newsletter subscribers and website visitors increased again.

- **86** new members
- **90+** national and international industry events & Swiss Biotech Academy courses
- **~230,000** web visitors from 190 countries
- **~58,000** info mailings
- **60+** media features
- **> 800** companies listed on Swiss Biotech Ventures platform
- **~5,600** LinkedIn followers
Partner network provides crucial advantages

The Swiss Biotech Association can reap several benefits from forming partnerships with other organizations. National and international partnerships help us to leverage our impact.

Access to a wider pool of resources
By partnering with other organizations, we can access a broader range of resources and exchange with specialized industry stakeholders. Our partnerships strengthen our voice and leverage our impact.

Increased credibility and visibility
Collaboration with reputable partners and policy makers increase the credibility and visibility of our association. This builds trust and confidence, and helps to optimize the framework for a successful industry development.

Improved information exchange
Our partners enable us to access and transfer more knowhow, to provide our stakeholders with privileged information, networking opportunities, international connectivity and access to technologies.

Amplified support for Swiss biotech ecosystem
Our partners help promote and improve our platforms and thus accelerate and amplify the support we can provide to the Swiss biotech stakeholders.

Check out our partners
Our partnerships help to...

- **...optimize framework conditions**
  Other associations, councils, committees and policy makers

- **...foster international collaborations & trade**
  International life science clusters, trade agencies, business hubs, and e.g. the Global Village at the Swiss Biotech Day

- **...promote competitive advantages**
  Promotion agencies, chambers of commerce, Swiss Biotech Report

- **...facilitate access to funding and partnering**
  Swiss Biotech Ventures platform, investors associations, international investment partners

- **...attract, educate and retain talent**
  Swiss Biotech Orbit platform and Swiss Biotech Association Academy partners

- **...seek and offer preferential conditions for our members**
  Equipment suppliers, insurances, event organizers, analysts, scientific publishers

- **...increase credibility & visibility of the industry**
  Media, Swiss Biotech Day, Swiss Biotech Success Stories, Swiss Biotech Report, international Swiss pavilions

- **...link to specialized stakeholders**
  Academia, technology transfer organizations, business development experts

- **...foster international collaborations & trade**
  International life science clusters, trade agencies, business hubs, and e.g. the Global Village at the Swiss Biotech Day
86 new members joined the association in 2022, shown in red

List of members, December 31, 2022

Bonetti & Partner GmbH
Bright Peak Therapeutics AG
Bromatech (Suisse) SA
Bucher Bietigheim AG
Büchi AG
Bühlmann Laboratories AG
C-CIT Sensors AG
Cabinet Privé de Conseils s.a. (CPC)
Caidya
Calliditas Therapeutics Suisse SA
Calypso Biotech SA
Cancer Research and Biotechnology AG
Canion AG
CanVirex AG
Caparna AG
Carbogen Amcis AG
CarthageGenetics Suisse Sarl
Catalent Pharma Solutions GmbH
Catalyze Switzerland GmbH
CDR-Life AG
CEBIS International
Celeron Switzerland AG
Cell Receptor SA
Celsestia Biotech AG
cellvie AG
Celonic AG
Cerbio-Pharma SA
Cerdia International GmbH
certus molecular diagnostics ag
Cetacea Consulting GmbH
Chemengineering Switzerland AG
Choose Life Biotech SA
Chondrel SA
Cilatun Biopharma Consulting AG
CimArk SA
Cimeio Therapeutics AG
CIS Pharma AG
Citeline
ClearView Healthcare Partners Switzerland GmbH
Clemmedi AG
ClinOps Advisory Turner GmbH
Connectors Verbindungstechnik AG
Consultants in Science Sarl
Coretag Therapeutics AG
Coulter Partners
CRB Group GmbH
Creoptx AG
CROSS Research SA - CROss Alliance®
CSEM
CSL Behring
CTC Resourcing Solutions AG
Culture Collection of Switzerland AG
Curatis AG
CUTISS AG
Cytiva Europe GmbH
Cytosurge AG
Cyxone Switzerland AG
D36.ch Sarl
Dai Tao GmbH
Debiopharm International SA
Deep Breath Intelligence AG
Demirurge Technologies AG
diaxxo AG
Dimercon Therapeutics AG
Dinaco AG
DPS Engineering Switzerland GmbH
Dr. Remus Muresan Legal Services
Drm, Dr. Mueller AG
ECS-Progastrin LAB SA
Effirx Pharmaceuticals SA
Elthera AG
Emergent BioSolutions
EraCal Therapeutics Ltd
EspeRare Fondation
Eurofins BioPharma Product Testing
Eurofins Genomics
Evitria AG
ExcellGene SA
ExpertInova AG
F. Hoffmann-La Roche AG
Fluidic Analytics Ltd
FluoSphere SA
Fortys1 Advisors AG
Fritz Gyger AG
Future Health Pharma GmbH
G&L Scientific (Schweiz) GmbH
Galsier SA
GBiotech Sarl
Genedata AG
GeNeuro SA
Geneva Biotech Center (GBC) SA
Genexa AG
GenSearch Switzerland
GliaPharm SA
GlycoEra AG
GMT Fine Chemicals SA
Gnubiotics Sciences Sàrl
Granite Bio SA
GT Gain Therapeutics SA
Haya Therapeutics SA
HBM Partners AG
headcount AG
Healthva SA
Health Advances GmbH
Healthcon AG
Helsinn Healthcare SA
Helvetia Biotech Sarl
Helvetia Health Care Sarl
HEMEX AG
HemostOD SA
Hengrui Europe Biosciences AG
HexagonFab Switzerland Ltd
HGf GmbH
Homburger AG
House of Lab Science AG
Humabs BioMed AG
Hyperbolic Holdings GmbH
Institute for Biopharmaceutical Research
Ichmos Sciences SA
ICON Clinical Research (Switzerland) GmbH
Ideogen AG
Idorsia Pharmaceuticals Ltd.
IE Life Science Engineering AG
ImmunO5 Therapeutics AG
InCephalo AG
Incyte Biosciences International Sàrl
Inforis AG
InnoMedica Holding AG
Innovative Sensor Technology AG
INQFEO AG
InsideReg Sarl
InSphere AG
Integra Biosciences AG
Integrated Biologix GmbH
InterAx Biotech AG
Inthera Bioscience AG
Invisight AG SA
IOntura SA
IPS Biopharma AG
IQone Healthcare Switzerland
IQVIA AG
Jacobs Switzerland GmbH
We enhance the visibility of biotech companies

These members profit from a cost-effective and easy-to-do marketing opportunity. For one year their logos feature on our communication tools. These include the Swiss Biotech Association exhibition booth at renowned conferences, publications, and presentations about the Swiss biotech industry for stakeholders, talents, partners, media, investors, and in one-on-one meetings.
Swiss Biotech Association board and management

The board

Dr. Patrick Amstutz
President
CEO Molecular Partners

Dr. Luca Bolliger
Vice President
CEO abcDNA

Dr. Jurgi Camblong
Vice President
CEO SOPHIA GENETICS

Dr. Bettina Ernst
Vice President
CEO BERNINA Bioinvest

Dr. Ulf Grawunder
Vice President
Managing Partner
Viopas Venture Consulting

Martin Howald
Vice President
Honorary Member
CEO BioConcept

Filippo Riva
Vice President
CEO Humabs Biomed

The management team

Dr. Michael Altorfer
CEO

Sabine Bamert
Head of Communications

Patrick Imwinkelried
Accounting
Wespi & Partner

Annamaria Kauzlaric
Member support

Dr. Carsten Laue
Funding & community platform

Fabio Napoletano
Head Business Development
Liaison Bern & Ticino

Dr. Franz Waibel
Head Global Village

Aditya Yellepeddi
Liaison Romandie
The Swiss Biotech Association

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

Our Mission

The Swiss Biotech Association is a non-profit, member-driven organization representing the interests of the Swiss biotech industry. Swiss biotech companies are leading the way in developing and commercializing innovative medicines, diagnostics, healthcare treatments, services and enabling technologies.

Our core objective is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation.

To this end, the Swiss Biotech Association is dedicated to supporting Swiss biotech companies through the following:

Developing favorable and competitive framework conditions

- Creating awareness of the biotech industry’s needs and interests with policy makers
- Advocating a competitive tax system alongside lean and pragmatic regulations
- Fostering life science education, technology transfer and intellectual property

Attracting talent, know-how and financial resources to drive innovation and growth

- Promoting and facilitating access to funding opportunities

Connecting investors and attractive biotech investment opportunities

Facilitating access to national and international talent

Fostering networking through strategic, national and international partnerships

- Connecting industry stakeholders and life science clusters
- Organizing and co-promoting national and international life science events
- Providing access to privileged information through industry platforms and working groups

Promoting the accomplishments of the Swiss biotech industry

- Disseminating the value-creation of Swiss biotech companies
- Visualizing the diversity and competitiveness of Swiss biotech companies
- Presenting innovative products and technologies and their contribution to quality of life
Preferential business solutions for our members

In collaboration with business solution partners, the Swiss Biotech Association creates value for its members by leveraging their combined purchasing power, resulting in significant cost savings for running their business. Should you have requirements for additional business solution partners, or like to become one, please let us know (see team on page 28).

Swiss Life’s pension fund
With the Swiss Biotech Association employee benefits solution, our members join forces and benefit from significantly more attractive risk and cost contributions for occupational benefits with Swiss Life.

Helvetia’s business insurance
Our members can cover their business risks with Helvetia’s individual and modular options. Their 8 in 1 discounted offer includes insurance for movable property, buildings and buildings liability, technical, marine, as well as assistance, legal protection, public and professional liability.

LubioScience’s portfolio
Our members benefit from special discounts on LubioScience’s entire portfolio of 4+ million antibodies, proteins, assay kits and lab reagents, and free shipping. They also can access their procurement services and custom services solutions.
**ProcEurope’s laboratory supplies**

Our members benefit from significant discounts on laboratory supplies and equipment, e.g. from Fisher Scientific by the European Life Sciences Purchasing Consortium.

**BioCentury’s market research**

A complimentary test access to BioCentury’s Intelligence platform, as well as discount on the subscription helps our members’ executives and investors solve business-critical decisions and to a better positioning by independent deep-dive analysis, high-quality data, and business intelligence on a global scale.

**Springer Nature’s leading publications**

The world’s leading scientific and technical publisher Springer Nature offers our members subscription discounts between 25% and 50% for some of their most exciting products.
What you can expect:
› Meet 1.100+ senior experts from the life science industry
› 70+ exhibitors and country booth
› Delegations from all over the world
› Swiss Biotech Success Stories Awards
› Innovative biotech start-ups and medium-sized biotech companies
› Thematically focused panel discussions
› Pre-scheduled one-to-one partnering meetings
› General Assembly of the Swiss Biotech Association

Sign in on our website at www.swissbiotechday.ch and stay updated about any news.
Supporting the Swiss biotech hub: Objectives 2023

The 2023 objectives of the Swiss Biotech Association link to one of the four mission pillars (see p. 29) or enhance the financial flexibility and operational effectiveness of the association.

Favorable frameworks

The Covid pandemic has made the importance of global co-operation painfully obvious. The vulnerability of single global supply chains and the risk that such supply chains can become part of political power grabs are also obvious. As a consequence, we see a strong trend back to national solutions and industry policies. While it is understandable that everyone seeks to reduce the dependency on unreliable processes, this trend risks severely hampering the international collaboration that is essential for innovation in the healthcare system.

The Swiss Biotech Association has established a tight network of partners in Switzerland and abroad, who are aligned around the shared objective to optimize global framework conditions for biotech startups and SMEs focusing on R&D (see p. 22–23).

In 2023, we will focus on:

- Re-establishing Switzerland’s full association with the Horizon Europe R&D program
- Opposing the proposed TRIPS (Trade Related Aspects of Intellectual Property Rights) waiver, which aims at weakening the international IP framework and thereby risks undermining biomedical innovation
- Reducing international differences in the approval process, the market exclusivity periods and the power of Orphan Drug Designation and fast track approvals
- Using the leading position in life science R&D to foster international collaboration and help innovate the global healthcare system

Talent and finance

The second pillar in our mission focuses on supporting Swiss-based biotech companies in accessing international talent, financial funding, and access to new technologies. When biotech companies have access to these critical resources, they can benefit from the competitive framework conditions that Switzerland offers. In 2023, the Swiss Biotech Association aims to support this mission objective by:

- Expanding the Swiss Biotech Orbit platform which is designed to attract and retain biotech talents and facilitate their matching with open job opportunities
- Further expanding professional education and training through our Academy platform
- Promoting and expanding the use of our online Swiss Biotech Ventures platform to facilitate matching of biotech companies, investors, and pharma partners
- Promoting the SPARKS segment of the Swiss Stock Exchange to facilitate access to capital markets for Swiss and European biotech SMEs
- Expanding the list of partnerships which offer business solutions that reduce operating costs for our members
Networking and information exchange

Our flagship event, the Swiss Biotech Day, will again play a central role in fostering information exchange and providing national and international networking opportunities. While this convention is focused on Swiss biotech startups and SMEs, it also attracts their business partners, namely international biotech investors, global pharma companies, specialized biotech CROs, and advisors and translational academic research groups that engage with industry partnerships in the context of public-private partnerships.

In 2023, the Swiss Biotech Day is held again in Basel. Building on the successful pilot edition of a partnering platform for international delegations – the Global Village – we are welcoming delegations from international biotech hubs that seek to strengthen their ties with Switzerland.

In 2023 we plan to strengthen networking opportunities by:

- Further growing the reach of the Swiss Biotech Day, including the embedded Global Village for international delegations
- Expanding the Swiss R&D Biotech CEO meeting platform at the end of January
- Extending the Swiss Biotech Insight meeting series
- Working closely with the Swiss Private Equity & Corporate Finance Association and Sachs Associates to exploit synergies with biotech investor meetings
- Launching new chapters to support industrial biotech applications and lab science and lab-automation

Promotion and awareness

The Swiss biotech hub is recognized as an attractive partner for R&D collaborations, international talents, academic institutions, and industry partners. International investors value the opportunities Switzerland can offer in this field. For twelve consecutive years, Switzerland has led the global innovation index published by the World Intellectual Property Organization.

We will continue to effectively present the strength and diversity of the more than 1,000 biotech companies that comprise the Swiss biotech sector. The Swiss Biotech Directory shows that Switzerland has established a very densely populated and highly diversified biotech hub with a strong international profile, covering all aspects of biotechnology.

Our 25th anniversary provides the opportunity to celebrate the many contributions and accomplishments the Swiss biotech industry has achieved during the past 25 years. We will further emphasize the importance of an effective framework and international partners, enabling us to retain this innovation power.

To support this in 2023, we will:

- Continue the digital and print edition of the Swiss Biotech Directory
- Publish the Swiss Biotech Report 2023, highlighting effective solutions to global challenges
- Present the Swiss Biotech Success Story Award to the 2023 laureates
- Expand the partner network to support industry promotion and raise awareness of Swiss biotech accomplishments and needs
Clear focus on what really matters

Aligning our objectives to our mission statement ensures a clear focus on what really matters. However, the priorities may vary and depend on the role and point of view of each stakeholder.

Swiss biotech industry

Leading position in drug manufacturing

CHF 2 billion per year R&D investments

50,000 jobs

> 1,000 companies

Biotech & pharma contribute ~ 40% to Swiss exports

~ CHF 1.5 billion new funds raised per year

Strong & sustainable growth

We see the strong growth of our membership base as an expression of trust and a confirmation that we are on the right track. We encourage you to continue to engage in an active dialogue with us to jointly shape the future of our industry and its framework and thereby keep Swiss biotech successful and competitive internationally.

Yours faithfully,

Michael Altorfer
CEO